Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IPH4102 · 2 trials · 4 indications
Using the Olsen (2011, JCO) criteria (All cohorts)
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Relapsed/refractory Sezary Syndrome | EXPERIMENTAL | IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity. |
| Cohort 2: Stage IB-IV Mycosis Fungoides, KIR3DL2 expressing | EXPERIMENTAL | IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity. |
| Cohort 3: Stage IB-IV Mycosis Fungoides,KIR3DL2 non-expressing (closed) | EXPERIMENTAL | IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity. |
| Cohort All comers: Stage IB-IV Mycosis Fungoides,KIR3DL2 expressing and non-expressing | EXPERIMENTAL | IPH4102 will be administered every week for 5 weeks then every 2 weeks for 10 administrations then every 4 weeks until disease progression or unacceptable toxicity. |
| IPH4102 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| IPH4102 | BIOLOGICAL | Patients will receive a flat dose of 750mg |
Inclusion criteria SS patients (Cohort 1): 1. Relapsed and/or refractory stage IVA, IVB SS who have received at least two prior systemic therapies; 2. Prior treatment with mogamulizumab; 3. Patients should have blood stage B2 at screening based on central evaluation by flow cytometry; 4. Feasibili...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | - | Undisclosed |
IPH4102 is an investigational monoclonal antibody being studied for the treatment of cutaneous T-cell lymphoma and other T-cell lymphomas. It has been evaluated in patients with relapsed or refractory cutaneous T-cell lymphomas and in advanced T-cell lymphoma, including mycosis fungoides and Sezary syndrome.
IPH4102 is being developed by Innate Pharma S.A., a biopharmaceutical company. The company's stock is listed under the ticker symbol IPHA.
IPH4102 has completed a Phase 1 clinical trial and a Phase 2 clinical trial. It remains an investigational drug and is not approved by regulatory authorities. The completed Phase 2 trial studied IPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma.
IPH4102 has been studied in two completed clinical trials. The Phase 1 trial NCT02593045 enrolled 44 patients with relapsed or refractory cutaneous T-cell lymphomas. The Phase 2 trial NCT03902184 enrolled 170 patients with advanced T-cell lymphoma, including mycosis fungoides and Sezary syndrome.
Yes, IPH4102 is also known as lacutamab. The Phase 2 clinical trial NCT03902184 is titled 'IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma,' confirming that both names refer to the same investigational drug.